Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Double-blind and Open-label Phases Meeting Abstract

authors

publication date

  • March 1, 2017

webpage

published in

start page

  • 433

end page

  • 434

volume

  • 46

issue

  • 3